特拉唑嗪(Terazosin)系喹唑啉的衍生物,是继哌唑嗪后研制的一种新型、长效α_1受体阻滞剂,化学结构与作用机理与哌唑嗪相似,但具有长效,副作用小,对血脂无不利影响。适用于轻、中度高血压,充血性心衰和雷诺氏病,可作为高血压的阶梯或维持治疗。最近美国食品药物管理管(FDA)已批准生产,列为抗高血压的常用药。 Terazosin is a novel and long-acting alpha 1 receptor blocker developed after prazosin, and its chemical structure and mechanism of action are similar to that of prazosin, but have long Effectiveness, side effects, no adverse effects on blood lipids. For mild to moderate hypertension, congestive heart failure and Raynaud’s disease, can be used as a ladder of hypertension or maintenance treatment. Recently the US Food and Drug Administration (FDA) has approved the production, as a commonly used anti-hypertensive drugs.